TEVA PHARMACEUTICAL INDUSTRIES LIMITED Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $47.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-07-29
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $47.00M, a 80.74% decline year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$121.00M, a 125.58% decline year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $84.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$44.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $757.00M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.00M 10-Q · filed 2026-07-29 | -$74.00M 10-Q · filed 2026-07-29 | $10.00M derived: sum of 3 quarters · filed 2026-07-29 | -$34.00M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$121.00M 10-Q · filed 2026-04-29 | -$37.00M derived: sum of 2 quarters · filed 2026-04-29 | -$81.00M derived: sum of 3 quarters · filed 2026-04-29 | $163.00M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $84.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-03 | $40.00M derived: sum of 2 quarters · filed 2026-02-03 | $284.00M derived: sum of 3 quarters · filed 2026-07-29 | $757.00M 10-K · filed 2026-02-03 |
| 2025-09-30 | -$44.00M 10-Q · filed 2025-11-05 | $200.00M derived: sum of 2 quarters · filed 2026-07-29 | $673.00M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $244.00M 10-Q · filed 2026-07-29 | $717.00M 10-Q · filed 2026-07-29 | ||
| 2025-03-31 | $473.00M 10-Q · filed 2026-04-29 | |||
| 2020-09-30 | $51.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $193.00M derived: sum of 2 quarters · filed 2021-10-27 | -$377.00M 10-Q · filed 2021-10-27 | |
| 2020-06-30 | $142.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | -$428.00M 10-Q · filed 2021-07-28 | ||
| 2020-03-31 | -$570.00M 10-Q · filed 2021-04-28 |